Moderna applies for emergency approval of COVID-19 vaccine they will request European authorization. The main analysis of the key clinical trial of Moderna’s vaccine confirms what the North American company has already been saying for days: that it reaches 94% of effectiveness, according to the data available. And with that data in hand, the pharmaceutical conglomerate has just announced that it will immediately request authorization from European and US regulators.
- Pfizer applies for emergency approval of COVID-19 vaccine in the US
- COVID-19 vaccine deliveries could start before Christmas
- Pfizer announces a 95% effective COVID-19 vaccine
Moderna reports 94.1% efficacy in COVID-19 vaccine
With this on the table and if the results are confirmed, everything seems to point to the fact that we will face 2021 with two SARS-CoV-2 vaccines. Moderna thus joins Pfizer’s strategy and adds pressure on health authorities who have to decide whether to give, for the first time, an “emergency use authorization” to a vaccine.
After a few days of uncertainty due to the doubts raised by the data on the Oxford and AstraZeneca vaccine, the results of Moderna (especially the observation that no vaccinated patient has developed a severe COVID) are an endorsement of the potential of mRNA vaccines which, despite their novelty, are managing to reduce development times without showing problems of safety or efficacy.
Moderna applies emergency approval of COVID-19 vaccine
Moderna applies for emergency approval of the COVID-19 vaccine and they will request European authorization. However, we are still moving in that unstable terrain of not having the data available. The regulators have yet to analyze the results of the study and give their approval. Moreover, they have yet to decide whether to grant “emergency use authorization” for these vaccines, although this has never been done before. People are expecting a vaccine before Christmas.
